Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Recalling firm

Ascend Laboratories, LLC

NDC code

67877-590-01

Origin

NJ, United States

Initiated by

Voluntary: Firm initiated

FDA recall number

D-0547-2026

Other Metoprolol recalls

See all

Class II · Moderate risk Ongoing Jan 29, 2026

Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054…

Reason Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc D-0357-2026

Class II · Moderate risk Ongoing Jan 29, 2026

Metoprolol Succinate Extended-Release Tablets, Rx Only, 100 mg, 100 tablets bottles (NDC: 45963-677-11) and 1,000 tablets bottles…

Reason Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc D-0356-2026

Class II · Moderate risk Ongoing Jan 29, 2026

Metoprolol Succinate Extended-Release Tablets, 50 mg, 100 tablets bottles (NDC: 45963-676-11) and 1,000 tablets bottles (NDC…

Reason Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc D-0355-2026

Class II · Moderate risk Ongoing Jan 29, 2026

Metoprolol Succinate Extended-Release Tablets, 25 mg, 100 tablets bottles (NDC: 45963-709-11) and 1,000 tablets bottles (NDC…

Reason Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc D-0354-2026

Class II · Moderate risk Ongoing Aug 6, 2025

Metoprolol Tartrate Tablets, USP, 100 mg, 1000 Tablets, Rx Only, Manufactured by: Renata PLC (General Plant -2), Noyapara, Bhawal…

Reason CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.

Westminster Pharmaceuticals LLC NDC 69367-355-10 D-0582-2025